Brought to you by 
OSI purchases drug discovery assets from Cadus
31 Aug 1999
Executive Summary
Unable to carry on after losing its patent battle with Sibia Neurosciences over G-protein based assays in yeast, Cadus Pharmaceuticals has sold its other drug discovery assets to OSI Pharmaceuticals (drug discovery technology and biotech drugs) for $1.5mm.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
OSI purchases drug discovery assets from Cadus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice